The effects of additional protein intake on muscle strength and physical performance in physically active elderly

The effects of additional protein intake on muscle strength and physical performance in physically active elderly - Prowalking

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON45732

Enrollment

120

Registered

2017-03-09

Start date

2017-03-22

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sarcopenie Muscle strength loss reduced phyiscal functionality

Interventions

The elderly will be randomly divided into the protein or placebo group. The daily supplementation consists of a protein product (30 grams of protein) or a placebo (consisting of carbohydrates). It w

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 65 years or older - Registered for the Nijmegen Four Days Marches 2017 - Protein intake less than 1.0 gram/kilogram bodyweight/day - Able to understand and perform the study procedures

Exclusion criteria

Exclusion criteria: - Type I or type II diabetes (fasted blood glucose level *7,0 mmol) - Allergic or sensitive for milk proteins, or lactose intolerant. - Having diagnosed COPD or treatmet with cancer - Having diagnosed renal insufficiency - Having diagnosed intestinal diseases influencing the uptake of protein (i.e. active inflammatory bowel disease, Crohn*s disease) - Use of statins - Involved in a heavy resistance type exercise program

Design outcomes

Primary

Measure	Time frame
The primary outcomes are differences in change in muscle strength and physical performance between the intervention and control group after 12 weeks. Moreover, muscle mass will be determined to assess differences between the intervention and control group. Primary outcome Maximal voluntary contraction (leg extension strength) of 3 repeated measures (3RM) and physical performance (determined with Short Physical Performance Battery (SPPB)).	—

Measure

Time frame

The primary outcomes are differences in change in muscle strength and physical performance between the intervention and control group after 12 weeks. Moreover, muscle mass will be determined to assess differences between the intervention and control group. Primary outcome Maximal voluntary contraction (leg extension strength) of 3 repeated measures (3RM) and physical performance (determined with Short Physical Performance Battery (SPPB)).

—

Secondary

Measure	Time frame
During the Four Days Marches we will assess differences between the protein-supplemented group and the placebo-supplemented group for recovery of physical performance, of muscle strength and biomarkers (muscle and joint). Secondary study parameters are changes in: o Muscle contractile function* o Handgrip strength (dynamometer) o Timed up-and-go (TUG) test o Anthropometrics o Body composition (DEXA) *Performed in a subgroup of 60 subjects (30 intervention, 30 placebo) Other parameters are: o Physical fitness (Åstrand-Rhyming test) o Physical activity (SQUASH) and exercise training (diary) o Daily dietary and protein intake (24h-recalls) o Compliance (protein supplementation) o Blood analyses (protein, glucose and insulin (for screening diabetes), creatinin (for screening renal insufficiency), inflammatory biomarkers, joint markers) o Urine analyses (protein, inflammatory biomarkers, joint markers) o Questionnaire screening sarcopenia (SARC-F) o Questionnaire quality of life (EQ5D) o Questionnaire muscle and joint pain (Short-Form McGill Pain Questionnaire (SF-MPQ) and Brief pain inventory vragenlijst (BPI-SF))	—

Measure

Time frame

During the Four Days Marches we will assess differences between the protein-supplemented group and the placebo-supplemented group for recovery of physical performance, of muscle strength and biomarkers (muscle and joint). Secondary study parameters are changes in: o Muscle contractile function* o Handgrip strength (dynamometer) o Timed up-and-go (TUG) test o Anthropometrics o Body composition (DEXA) *Performed in a subgroup of 60 subjects (30 intervention, 30 placebo) Other parameters are: o Physical fitness (Åstrand-Rhyming test) o Physical activity (SQUASH) and exercise training (diary) o Daily dietary and protein intake (24h-recalls) o Compliance (protein supplementation) o Blood analyses (protein, glucose and insulin (for screening diabetes), creatinin (for screening renal insufficiency), inflammatory biomarkers, joint markers) o Urine analyses (protein, inflammatory biomarkers, joint markers) o Questionnaire screening sarcopenia (SARC-F) o Questionnaire quality of life (EQ5D) o Questionnaire muscle and joint pain (Short-Form McGill Pain Questionnaire (SF-MPQ) and Brief pain inventory vragenlijst (BPI-SF))

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)